600587 新华医疗
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入7,355,2845.41%9,736,09010,020,61910,011,8689,281,769
减:营业总成本6,854,4355.17%9,132,0539,224,3419,238,9908,682,124
    其中:营业成本5,557,6506.35%7,287,7647,409,6877,360,4806,827,779
               财务费用28,73934.94%27,51319,10414,40336,629
               资产减值损失(54,164)82.68%(78,504)(70,302)(47,478)(51,846)
公允价值变动收益--------12,536(43,356)
投资收益(29,827)-161.78%39,10170,82381,11849,726
    其中:对联营企业和合营企业的投资收益(30,878)7,869.55%(11,009)63,14674,33262,105
营业利润434,499-16.18%590,867798,517756,953585,833
利润总额438,353-15.45%591,121795,661738,579576,094
减:所得税费用77,9424.80%62,986103,76462,07849,179
净利润360,411-18.84%528,135691,897676,501526,914
减:非控股权益(324)-103.31%1,79928722,50426,842
股东净利润360,735-16.94%526,336691,610653,997500,072

市场价值指针
每股收益 (元) *0.600-16.67%0.8701.1401.1001.230
每股派息 (元) *----0.3500.2500.5000.150
每股净资产 (元) *13.2161.43%12.70512.64415.68213.091
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容